Cell division is a highly regulated process. Checkpoints can halt cell-cycle progression due to adverse conditions such as misalignment of chromosomes to prevent missegregation. The search for new regulators of the cell cycle revealed the mitotic checkpoint gene CHFR (checkpoint with forkhead-associated and ring finger). CHFR coordinates an early mitotic phase by delaying chromosome condensation in response to a mitotic stress. Because aneuploidy and chromosome instability are common in malignant breast tumors, we screened 24 breast cancer cell lines for CHFR expression and demonstrated that 50% (12 of 24) of breast cancer cell lines had low CHFR levels. Expression of CHFR was reactivated with the demethylating agent 5-aza-2 0 -deoxycytidine (5-aza-dC) in two low-CHFR-expressing cell lines. Eleven of these 12 (92%) low-CHFR-expressing cell lines had an unusually high number of condensed chromosomes and high mitotic indices in response to nocodazole treatment. Transfection of CHFR in one of these cancer cell lines lowered the mitotic index after nocodazole treatment. In conclusion, our data suggested that low CHFR expression associated with high mitotic indices in response to nocodazole treatment were common in the breast cancer cell lines studied. Additional flow cytometry studies and analysis of a protein that interacts with CHFR in vitro, polo-like kinase 1 (PLK1), suggests that this CHFR-associated early G 2 /M checkpoint is complex, involving additional, as yet unidentified, proteins. Further analysis of CHFR in breast cancer cells will be important for understanding the complex mechanisms leading to aneuploidy and chromosomal instability observed in breast cancer. ß
INTRODUCTION
The somatic cell cycle is a highly regulated process with checkpoints that maintain normal progression through each phase and insure that each step takes place without errors. Checkpoints monitor G 1 /S and G 2 /M transitions where cancer related defects can occur. Mutations that disrupt some checkpoint genes have been linked to genetic instability observed in cancer cells [1] . CHFR (checkpoint with forkheadassociated and ring finger) is a recently identified checkpoint gene that functions at the early G 2 /M phase [2] . G 2 to M phase progression in the cell cycle is controlled at least in part by the cell division cycle 2 (CDC2)/cyclin B1 complex [3] . Cyclin B1 starts to accumulate and associates with CDC2 to form the mitosis promoting factor (MPF) complex as cells enter prophase [4, 5] . The MPF complex is then transported to the nucleus and kept inactive by WEE1 and MYT1 kinases, which phosphorylate CDC2 [6] [7] [8] [9] [10] . CDC25C dephosphorylates CDC2 to activate the MPF complex so that the cell can proceed into prometaphase where chromosomes condense, nuclear envelope breaks down, and mitotic spindles form [11] [12] [13] [14] .
Recent studies demonstrate that CHFR functions as an important checkpoint protein early in the G 2 /M transition and its activation delays the cell cycle in prophase, preventing chromosome condensation in response to a mitotic stress by prolonging the inhibitory phosphorylation state (Tyr15) of CDC2 in vitro [2, 15] . Initial analysis indicates that the CHFR-associated G 2 /M checkpoint is inactivated, as demonstrated by high mitotic indices due to lack of CHFR expression or CHFR mutations in a neuroblastoma, an osteosarcoma, and two colon cancer cell lines (four of eight different cancer cell lines) [2] . Further studies also found hypermethylation of the CHFR promoter in a variety of cancer cell lines, including esophageal, colon, lung, osteosarcoma, central nervous system, leukemic and primary tumors of the colon, lung, and esophagus [16] [17] [18] [19] suggesting that decreased expression is associated with the observed malignant phenotype.
Currently it is unclear which in vivo events trigger activation of the CHFR-associated G 2 /M checkpoint. The fact that nocodazole is a microtubule depolymerizing agent that can activate the checkpoint before the formation of microtubule spindles suggests that early events dependent on microtubules, such as centrosome duplication and centrosome separation, may be monitored by this checkpoint. Defects in centrosome duplication or separation are already known to be associated with genetic instability [20] [21] [22] .
Because genetic instability and aneuploidy are very common in malignant breast cancers, we hypothesized that defects in the CHFR-associated G 2 /M checkpoint could be an important step leading to aneuploidy and genetic instability during breast tumorigenesis. In this study, we examined the CHFRassociated G 2 /M checkpoint and expression levels of CHFR in breast cancer cell lines to improve our understanding of this early checkpoint and to investigate its potential role in mammary tumorigenesis.
MATERIALS AND METHODS

Cell Lines
SUM149, SUM159, SUM229, SUM52, SUM102, SUM225, SUM1315, SUM185, and human papilloma virus (HPV)-immortalized nontumorigenic mammary cell lines were developed and provided by SP Ethier at the University of Michigan Comprehensive Cancer Center [23] [24] [25] [26] . Other cancer cell lines (BT20, CAL51, DU4475, Hs578T, MDA-MB361,  MDA-MB435, MCF10A, DLD-1, MCF7, MDA-MB468, MDA-MB157, BT474, T47D, BT549, MDA-MB231, MDA-MB453, and SK-BR-3) were obtained from American Type Culture Collection (Manassas, VA) and grown under recommended conditions.
RNA Isolation and Northern Blot Analysis
RNA isolation and Northern blot analysis were performed as previously described [27] . Polymerase chain reaction (PCR) products of 1.1 kb for CHFR (F: CAGGATCAGGAGGATTTGGA, R: AGTCAGGACG-GGATGTTACG) and 0.4 kb for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (F: GGGAGC-CAAAAGGGTCATCA, R: TTTCTAGACGGCAGGTC-AGGT) were used to generate probes by random priming with [a- 32 P] dCTP [28] . Band intensities were examined by visual inspection and quantified by densitometry (Alpha Innotech IS-1000 Digital Imaging System, Version 2.00).
Conformation Sensitive Gel Electrophoresis (CSGE) Analysis
Primers were designed to amplify CHFR coding sequence such that the PCR products were no more than 650 bp and they overlapped with neighboring PCR products ( Table 1 ). Five micrograms of RNA was used to generate cDNA with oligo (dT) primers with the Superscript Preamplification System (GibcoBRL, Rockville, MD). Reverse transcriptase (RT)-PCR products were electrophoresed and visualized on a 3% agarose gel stained with ethidium-bromide. Three to five microliters of breast cancer and HPV11-21 cell line RT-PCR products were mixed to facilitate the heteroduplex formation. The mixtures were denatured at 958C for 5 min, allowed to reanneal at 688C for 30 min and analyzed by CSGE as previously described [29] . Bands were visualized after electrophoresis by ethidium-bromide staining. Samples that formed heteroduplexes were electrophoresed on agarose gels, gel purified (Qiagen, Valencia, CA), and sequenced at the University of Michigan Sequencing Core. *CSGE, conformation sensitive gel electrophoresis; CHFR, checkpoint with forkhead-associated and ring finger. Some polymerase chain reactions (PCRs) included three cycles with the first annealing temperature, followed by three cycles at the middle temperature and 29 cycles at the lowest annealing temperature or 35 cycles with a single annealing temperature.
{
Denotes a PCR product that was initially predicted to be 387 bp according to NM_018223, however, this primer set amplified a 500 bp product which is consistent with AF170724.
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Methylation and Histone Modification Analysis
Cells were treated with 10 mM 5-aza-2 0 -deoxycytidine (5-aza-dC) (Sigma, St. Louis, MO) for 96 h or with 0.5 mM trichostatin A (TSA) (Sigma) for 24 h. Medium was aspirated off and replaced every 24 h with fresh medium for 5-aza-dC treatment. RNA from treated and untreated cells was collected as described above at the end of incubation and analyzed by Northern blot analysis for CHFR expression.
Mitotic Index Analysis
Actively growing breast cancer cell lines at 70-80% confluency were treated with 200 ng/mL nocodazole (Sigma) [1] for 16 h [2] . After 16 h, the media were aspirated off and cells were rinsed and trypsinized according to manufacturer's suggestions prior to incubation with a hypotonic solution of 0.075 M potassium chloride for 20 min. After centrifugation at 800 Â g for 5 min, the potassium chloride solution was discarded and cells were fixed in 3:1 methanol and glacial acetic mixture. Cells were dropped onto microscope slides and stained with 0.2 mg/L Giemsa stain (GibcoBRL) for 10 min, after which the slides were rinsed with phosphate buffered saline. Nine hundred cells were counted on average for each cell line. Mitotic indices were calculated based on the percentage of cells that were in any stage of mitosis with visibly condensed chromosomes as analyzed by light microscopy. Mitotic indices less than 50% were considered ''low,'' whereas indices more than 50% were considered ''high.''
Transient CHFR Transfections
A full-length CHFR cDNA clone was generously provided by Scholnick and Halazonetis [2] . CHFR cDNA was cloned into the HindIII and NotI sites of retroviral pLNCX2 vector (BD Biosciences Clontech, Palo Alto, CA). The packaging cell line PT67 was transfected with 6 mg of DNA and 12 mL of FuGENE6 (Roche, Indianapolis, IN). Hs578T cells were infected with supernatants from PT67 cells transfected with retroviral empty pLNCX2 vector, pLNCX2-CHFR, and pLNCX2-LacZ constructs. The medium was replaced with fresh medium and nocodazole was added 36 h after infection [2] . The mitotic index was determined as described. RNA was isolated and cDNA was synthesized with RNeasy and Omniscript RT kits (Qiagen) to determine levels of CHFR expression. CHFR and GAPDH were co-amplified in a semiquantitative RT-PCR reaction and CHFR/GAPDH ratios were calculated following methods previously described [27] . X-gal staining was performed by standard methods as a control for infection efficiency in the pLNCX2-LacZ infected Hs578T cells.
Cell Synchronization and Flow Cytometric Analysis of Cell Cycle
Cells were synchronized at G 1 /S as described [2] . 1 Â 10 6 control or nocodazole-treated cells were collected and resuspended in 0.1% sodium citrate, 0.1% Triton X, 100 mg/mL Rnase, and 50 mg/mL propidium iodide. Cells were then analyzed for DNA content at the University of Michigan Flow Cytometry Core. Cell-cycle profiles of synchronized cell lines were also confirmed by flow cytometry. G 2 -M/ G 1 ratios were determined to estimate if cells were in mitosis. Cell lines with a threefold increase of G 2 -M/G 1 ratios were considered to be in mitosis after nocodazole treatment.
Western Blot Analysis
Fifty micrograms of whole cell lysates was used from breast cancer cell lines. Western blot analysis was performed as previously described [30] . The following antibodies were used: rabbit antibody specific to the phosphorylated inactive form of CDC2 (phospho-CDC2-Tyr15) was purchased from Cell Signalling (Beverly, MA) and used 1:1000 dilution. Mouse polo-like kinase 1 (PLK1) antibody was received from Zymed Laboratories (San Francisco, CA) and used 1:500 dilution. Mouse actin antibody (used as a loading control) (1:1000), goat antirabbit (1:7500) and rabbit antimouse antibodies (1:5000 for PLK1 and 1:1200 for actin) were purchased from Sigma.
RESULTS
Expression Analysis of CHFR in Breast Cancer Cells
Northern blot analysis revealed that 12 of 24 breast cancer cell lines had low or no CHFR expression (Figure 1) . By RT-PCR, we were able to amplify the CHFR coding region even in the cell lines that did not show expression by Northern blot analysis, indicating low level of expression (e.g., DU4475).
Mutation and Methylation Analysis of CHFR
To determine if specific mutations inactivate CHFR or decrease CHFR expression, the coding region of CHFR was screened in all 24 breast cancer cell lines by CSGE. We found several sequence variants, but no predicted pathogenic alterations were detected in any of the cell lines (Table 2 ). Cell lines with low CHFR expression were then treated with both the demethylating agent 5-aza-dC and histone deacetylase inhibitor TSA. Northern blot analysis revealed that after 5-aza-dC treatment, CHFR expression was reactivated in two cell lines (MDA-MB435 and SUM52) (Figure 2 ). However, 5-aza-dC and TSA cotreatment did not cause an enhanced response in these cells compared to 5-aza-dC treatment only. In addition, we did not observe any increase of CHFR expression in the other cell lines with low CHFR levels after TSA treatment (data not shown). MDA-MB468 had low levels of CHFR transcript, but, unlike the other 11 cell lines with low-CHFR expression, this cell line demonstrated a low mitotic index after treatment with nocodazole. To delineate further the dynamics of cell-cycle progression through G 2 /M in the low mitotic index cells, we analyzed the DNA content in these cells by flow cytometry analysis. The ratios of G 2 -M (4 N) to G 1 (2 N) populations were determined to estimate if cells were arrested in mitosis or exited mitosis after nocodazole treatment (Table 3) . MCF7, MDA-MB157, BT474, and SUM102 cell lines had more than threefold increase of the G 2 -M/G 1 ratios after nocodazole treatment. However, no significant increase was observed in MDA-MB468, T-47D, BT549, or SUM225.
In the case of BT474, the mitotic index was 46%, which was close to our top cut-off value (50%) for categorizing lines as having low mitotic indices. Therefore, this cell line required further molecular characterization. BT474 cells were synchronized at the G 1 /S border and nocodazole was introduced 12 h after G 1 /S release [2] . The phosphorylation level of CDC2-Tyr 15 did not change in BT474 cells, Figure 1 . Low CHFR (checkpoint with forkhead-associated and ring finger) expression was detected in 50% (12 of 24) of breast cancer cell lines by Northern blot analysis. HPV5-24 was a human papilloma virus (HPV) immortalized mammary cell line and it was used as a positive control for CHFR expression but was not included in percentage calculations. Samples with the asterisks had low CHFR expression relative to other samples and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. The mean CHFR/GAPDH ratio determined by densitometry was 0.4 for low-CHFR-expressing cells, whereas it was two for higher CHFR-expressing cells, including HPV5-24. Hybridization of GAPDH probe was used to assess equal loading of samples. Ethidium bromide staining of ribosomal RNA on agarose gels was consistent with both running and loading patterns of the samples assessed by GAPDH hybridization (data not shown). 
{
The genotypes of these cell lines were not known with respect to the number of alleles present; thus it was not clear if these samples were hemizygous or homozygous for the sequence changes.
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whereas in a high mitotic index, low-CHFR expressing cell line Hs578T, the level of phosphorylation after nocodazole treatment decreased (Figure 4) . Five of 12 (42%) breast cancer cell lines (SUM1315, MDA-MB231, MDA-MB453, SUM185, and SK-BR-3) that had high levels of CHFR expression, also demonstrated high mitotic indices in response to nocodazole.
Expression Analysis for the CHFR Interacting Protein PLK1
Because the only known CHFR interacting protein is PLK1, we examined PLK1 levels in the same 24 breast cancer cell lines. Variable levels of PLK1 expression were detected in these breast cancer cell lines; however, there were no correlating patterns of PLK1 expression with the response of cells to nocodazole or with CHFR levels ( Figure 5A ). When levels of PLK1 in synchronized cells (Hs578T and BT474) were examined, no changes were detected after nocodazole treatment, regardless of CHFR levels in these cells ( Figure 5B ).
DISCUSSION
Studies report that CHFR expression is ubiquitous in normal human tissues and that lack of CHFR expression or mutations of CHFR is associated with early G 2 /M checkpoint defects in various cancers [2] . Here, we report that 50% (12 of 24) of breast cancer cell lines had low levels of CHFR expression. No pathogenic sequence alterations were found in any of the 24 breast cancer cells. The sequence variant that caused an amino acid change (Ala497 to Val) in two high-CHFR-expressing cells was reported to be a polymorphism [16] . However, we cannot eliminate the possibility of undetected mutations or alterations. The lack of significant sequence alterations in any of the cell lines led us to examine the possibility Figure 2 . 5-Aza-2 0 -deoxycytidine (5-aza-dC) treatment reactivated transcription of CHFR in two cells lines that had low-CHFR levels. Cells were treated with 10 mM 5-aza-dC for 96 h. RNA was isolated as described and expression of CHFR was detected by Northern blot analysis. Figure 3 . Eleven of 12 (92%) low-CHFR-expressing cells had high mitotic indices. Cells were treated with nocodazole and mitotic indices were determined based on the percentage of cells with condensed chromosomes. DLD-1 is a colon cancer cell line that lacks CHFR expression, has a high mitotic index in response to nocodazole [2] , and was used as a control in this experiment but was not included in percentage calculations. Dark gray bars, cell lines that had low-CHFR expression and high (more than 50%)-mitotic indices; white bars, high-CHFR expression, low (less than 50%)-mitotic indices; horizontally dashed bar, the only cell line that had low CHFR and low (less than 50%) mitotic index; and diagonally dashed bars, high-CHFR expression, high (more than 50%)-mitotic indices.
of hypermethylation or histone modification of the CHFR promoter in low-CHFR-expressing cell lines because such alterations are reported as common mechanisms of CHFR silencing in different cancer types [16] [17] [18] [19] . Data showed that CHFR was reactivated in two cell lines after treatment with a demethylating agent, suggesting other mechanisms to be more common than epigenetic regulation to account for low CHFR expression in breast cancer cells.
Lack of CHFR expression or mutations of CHFR have been associated with high mitotic indices and abnormal response to mitotic stress in cancer cells [2, 19, 31] . Consistent with previous data, 11 of 12 (92%) low-CHFR-expressing breast cancer cell lines demonstrated high mitotic indices in response to nocodazole treatment. Transient transfection of CHFR into Hs578T, a cell line which had low CHFR expression and a high mitotic index after nocodazole treatment, lowered the mitotic index after nocodazole treatment, suggesting that the high mitotic index seen in nocodazole treated Hs578T cells was at least in part due to low CHFR levels. Among the other low-CHFR-expressing cells we tried to transfect, Hs578T was the only successfully transfected cell line. This observation is also consistent with previous studies reporting difficulty of transfecting CHFR into mammalian cells and the growth disadvantage presumably resulted from CHFR overexpression [15, 19] .
The only cell line of 12 with low CHFR expression that also demonstrated low mitotic index was MDA-MB468. Cell-cycle analysis of low mitotic index cells after nocodazole treatment revealed that four cell lines including MDA-MB468 failed to arrest in mitosis and had exited mitosis possibly due to defects in both the early G 2 /M and spindle checkpoints.
To further characterize ''low'' and ''high'' mitotic index cell lines, dephosphorylation of CDC2 as a marker of mitotic progression was investigated in two cell lines from both groups because CHFR delays dephosphorylation of CDC2 in response to a mitotic Hs578T and BT474 cells were synchronized at G 1 /S border by thymidine and thymidine/deoxyctidine, aphidicolin block. Lysates were collected at G 1 /S border, 12 h after G 1 /S release and after mitotic stress was induced. Mitotic stress was induced 12 h after G 1 /S block [2] . 
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stress [15] . Inhibitory Tyr15 phosphorylation of CDC2 was detected in BT474 in support of CHFRactivated early G 2 /M checkpoint arrest. The Hs578T cell line, which had low CHFR expression and displayed high mitotic index, demonstrated decreased Tyr15 phosphorylation of CDC2, indicating activation of CDC2 and thus mitotic progression.
Interestingly, five of 12 (48%) high-CHFR expressing cell lines also had high mitotic indices, suggesting the presence of other proteins involved in this early G 2 /M checkpoint or CHFR inactivation due to undetected mutations. The only other protein interacting with CHFR reported to date is PLK1. In Xenopus cell-free extracts, CHFR can ubiquitinate PLK1 for degradation through its ubiquitin ligase activity [15, 31] . Therefore, we examined the levels of PLK1 in the 24 breast cancer cell lines, but no correlation was found between PLK1 levels and mitotic index or CHFR. In addition, no changes were detected in PLK1 levels after nocodazole treatment that would trigger activation of the CHFR-associated early G 2 /M checkpoint in synchronized cells. The in vitro ubiquitination of PLK1 by CHFR may actually involve more complex interactions in vivo. As we begin to understand how this checkpoint functions, we will be better able to investigate how the molecular interactions take place in the cell when the checkpoint is activated.
In this study, we report that low CHFR expression and high mitotic indices after nocodazole treatment were common in breast cancer cells. The high incidence of low CHFR expression associated with an unexpectedly high percentage of condensed chromosomes after nocodazole treatment in breast cancer cell lines may suggest a potential role for CHFR and the early G 2 /M checkpoint. CHFR and its role in the early G 2 /M checkpoint need to be further explored to reveal the in vivo conditions that activate this pathway, response of the pathway to different drugs, and key proteins that may function in this or related pathways. Analysis of CHFR expression in additional breast cancer cells, including primary breast tumors, with a highly specific CHFR antibody as well as in vivo analysis in animal models, will help elucidate the significance of CHFR alterations in human breast cancers. Elucidation of this CHFR checkpoint should help us better understand the genetic instability commonly observed in malignant lesions and may provide important insights for cancer therapy.
